LONDON (Alliance News) - GlaxoSmithKline PLC's ViiV Healthcare signed a strategic manufacturing agreement with Desano Pharmaceuticals on Thursday for the manufacturing of dolutegravir, ViiV's HIV medicine.
The agreement will offer an additional source of the dolutegravir active pharmaceutical ingredient and will allow ViiV to offer a competitive supply of the finished product, marketed under the name Tivicay, for China and a number of developing countries, subject to national approvals.
"This manufacturing agreement with Desano for dolutegravir is a significant achievement to facilitate access to our medicines. With our recent agreement with the Medicines Patent Pool and our other access initiatives this deal is aligned with our ongoing commitment to improve access to our medicines in countries where the need is greatest." said Dominique Limet, chief executive officer of ViiV Healthcare.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)